Edgestream Partners L.P. Purchases Shares of 152,159 Certara, Inc. (NASDAQ:CERT)

Edgestream Partners L.P. purchased a new stake in Certara, Inc. (NASDAQ:CERT) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 152,159 shares of the company’s stock, valued at approximately $1,782,000.

A number of other hedge funds also recently bought and sold shares of CERT. The Manufacturers Life Insurance Company raised its holdings in Certara by 4.5% during the second quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after purchasing an additional 975 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in Certara by 2.3% during the second quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company’s stock worth $751,000 after purchasing an additional 1,200 shares in the last quarter. Nicolet Advisory Services LLC raised its holdings in Certara by 6.6% during the third quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock worth $273,000 after purchasing an additional 1,531 shares in the last quarter. KBC Group NV raised its holdings in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Finally, Blue Trust Inc. acquired a new stake in Certara during the second quarter worth approximately $26,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Robert W. Baird cut their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Barclays cut their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Finally, UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Certara has a consensus rating of “Hold” and an average price target of $15.92.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Certara Stock Down 0.3 %

CERT opened at $11.26 on Wednesday. The business has a 50 day moving average price of $10.82 and a two-hundred day moving average price of $12.94. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, equities research analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.